Regeneron Pharmaceuticals
(NASDAQ) REGN
Regeneron Pharmaceuticals Financials at a Glance
Market Cap
$65.01B
Revenue (TTM)
$14.92B
Net Income (TTM)
$4.42B
EPS (TTM)
$41.04
P/E Ratio
15.11
Dividend
$3.64
Beta (Volatility)
0.60 (Low)
Dividend
$3.64
Beta (Volatility)
0.60 (Low)
Price
$633.30
Volume
41,573
Open
$626.72
Price
$633.30
Volume
41,573
Open
$626.72
Previous Close
$633.30
Daily Range
$626.60 - $638.62
52-Week Range
$517.39 - $821.11
Estimated Earnings Date
Jul 30, 2026
Dividend
$3.64
Beta (Volatility)
0.60 (Low)
Price
$633.30
Volume
41,573
Open
$626.72
Previous Close
$633.30
Daily Range
$626.60 - $638.62
52-Week Range
$517.39 - $821.11
Estimated Earnings Date
Jul 30, 2026
REGN News
Best Biotech ETFs to Buy in 2026
REGN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Regeneron Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
15,410
CEO
Leonard S. Schleifer, MD, PhD
Website
www.regeneron.comHeadquarters
Tarrytown, NY 10591-6707, US
REGN Financials
Key Financial Metrics (TTM)
Gross Margin
84.55%
Operating Margin
24.32%
Net Income Margin
29.65%
Return on Equity
14.32%
Return on Capital
10.53%
Return on Assets
10.82%
Earnings Yield
6.62%
Dividend Yield
0.59%
Payout Ratio
8.46%
Stock Overview
Market Cap
$65.01B
Shares Outstanding
104.84M
Volume
41.57K
Avg. Volume
959.38K
Financials (TTM)
Gross Profit
$12.61B
Operating Income
$3.63B
EBITDA
$5.74B
Operating Cash Flow
$5.01B
Capital Expenditure
-$857.50M
Free Cash Flow
$4.16B
Cash & ST Invst.
$8.75B
Total Debt
$2.71B
Regeneron Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$3.61B
+19.0%
Gross Profit
$2.94B
+14.5%
Gross Margin
81.43%
N/A
Market Cap
$65.01B
N/A
Market Cap/Employee
$4.29M
N/A
Employees
15,158
N/A
Net Income
$727.20M
-10.1%
EBITDA
$967.30M
-7.0%
Quarterly Fundamentals
Total Cash
$8.75B
+4.8%
Total Debt
$2.71B
+0.1%
Accounts Receivable
$5.73B
+3.1%
Inventory
$3.10B
-2.8%
Long Term Debt
$1.99B
-26.6%
Short Term Debt
$720.00M
N/A
Return on Assets
10.82%
N/A
Return on Invested Capital
10.15%
N/A
Free Cash Flow
$848.30M
+9.7%
Operating Cash Flow
$1.08B
+3.2%